Artwork

Content provided by The Lancet and The Lancet Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet and The Lancet Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

In conversation with... Caroline Robert

10:45
 
Share
 

Manage episode 485519829 series 2409123
Content provided by The Lancet and The Lancet Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet and The Lancet Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial on the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations.

  continue reading

211 episodes

Artwork
iconShare
 
Manage episode 485519829 series 2409123
Content provided by The Lancet and The Lancet Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet and The Lancet Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial on the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations.

  continue reading

211 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play